Allergy-Clinical Immunology Market Analysis and Reports | Russia Conference Series

Market Analysis - Allergy-Clinical Immunology 2018

Allergy & Asthma affect millions of people every year all over the world

An Allergy is a hypersensitivity disorder of the immune system. It is an immunologically mediated reaction to a foreign antigen, resulting in abnormally intense immune responses, which cause tissue inflammation and organ dysfunction. Common allergic reactions include eczema, hives, hay fever, asthma attacks, food allergies, and reactions to the venom of stinging insects. Allergy victims are estimated to number around 60 to 70 million in the United States, with hay fever being the most common.

Allergic diseases include fatal anaphylaxis, food allergies, certain forms of asthma, rhinitis, conjunctivitis, angioedema, urticarial, eczema, eosinophilia disorders, including eosinophilia esophagitis, and drug and insect allergies. Globally, 300 million people are affected from asthma and about 200 to 250 million people are affected from food allergies. One tenth of the population endure from drug allergies and 400 million from rhinitis. Moreover, allergic diseases commonly occur together in the same individual, one disease with the other. This requires a collective approach to diagnosis and treatment and greater understanding of the underlying causes amongst family physicians, patients as well as specialists.

Allergy is expected to affect more than 50% of all Europeans in 10 years' time, 10% of children and adults under the age of 45 have 2 or more allergies. An estimated 21 million adults in the UK suffer from at least one allergy. Up to 1 in 5 allergic people suffer a serious debilitating disease and are in fear of death from a possible asthma attack or anaphylactic shock.


Asthma is a chronic respiratory disease characterized by frequent breathlessness and wheezing, which occur in acute events known as attacks. These attacks can vary significantly in occurrence and severity, and consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Collaborators of the Global Initiative for Asthma believe that as many as 300 million people worldwide are greatly impacted by asthma in their daily lives

According to the World Health Organization, the figure of patients suffering from asthma is 300 million and with the increasing trends it is expected to rise to 400 million, by 2025. Patients with asthma and allergic diseases have a lessened quality of life.

World Health Organization estimates asthma is the reason for 250,000 deaths per annum. Moreover, asthma in infants often goes unidentified and thus untreated. In the United States, 23 million people including 7 million children are affected from asthma and the prevalence is increasing. US is the single biggest asthma treatment market globally, reflecting the country’s large population size, high disease prevalence and the inflated cost of therapeutics in comparison with other major markets.

Market Update of Allergy & Asthma:

The occurrence of allergic diseases and asthma are increasing all over the world, particularly in low and middle income countries. Moreover, the complexity and severity of allergic diseases, including asthma, continue to raise high especially in children and young adults.

In order to address this universal challenge that threatens health and economies alike it is important to have a universal action plan that includes partnerships involving various stakeholders from low-, middle-, and high-income countries.

Geographic regions:

Global allergy treatment market is segmented into seven key regions:

North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan and Middle East & Africa.

North America followed by Europe dominates the global allergy treatment market due to increasing number of patients with various types of allergies including respiratory allergy, skin allergy, eye allergy, etc. growing environmental pollution, developed healthcare infrastructure and growing demand for immunotherapy for treatment of allergies in these region.

Asia-Pacific is the fastest emerging market for global allergy treatment due to growing allergic patient population, increasing awareness about advanced immunotherapy for treatment of allergies available in the market, developing healthcare infrastructure and rising government spending in healthcare industry in this region.

The global allergy diagnostics market is expected to reach USD 5.34 Billion by 2021 from USD 2.98 Billion in 2016, at a CAGR of 12.4%. The global market is broadly classified by product, test, allergen, end user, and region. £900million per annum spent by Primary Care is due to allergy. £68million per annum is the cost of hospital admissions due to allergy

Some of the key market players in global allergy treatment market are

·         Allergy therapeutics,

·         Allergopharma,

·         Allergon AB,

·         Alerpharma S.A,

·         Allergan, Inc.,

·         Genentech Inc.,

·         Schering-Plough Corporation,

·         McNeil Consumer Healthcare,

·         Collegium Pharmaceutical, Inc.,

·         Meda Pharmaceuticals, Inc,

Rates of asthma have increased significantly between the 1960s and 2008 with it being recognized as a major public health problem since the 1970s.  By 2025, asthma will represent the most prevalent chronic childhood disease and result in one of the highest causes of health care costs. 17.7 million Adults & 6.3 million children in US currently have Asthma.

According to the Centres for Disease Control,

·         1 in 14 people have asthma in US.

·         Asthma cost the US about $56 billion in medical costs, lost school and work days, and early deaths

·         In Europe, about 30 million children and adults less than 45 years old have asthma.

·         Asthma affects one in every 11 people and one in five households in UK.

·         Every 10 seconds someone is having a potentially life-threatening asthma attack in the UK

·         5.4 million People in the UK are currently receiving treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12).

The global asthma therapeutics market accounted for USD 21.3 billion as of 2016 and is anticipated to exhibit a sluggish growth rate of 2.2% over the forecast period. On the other hand, increasing incidences of respiratory diseases coupled with the demand for cost-effective treatment options is expected to drive the asthma therapeutics market growth during the forecast period from 2016 to 2024.

Some of the key players in this market are:

•           AstraZeneca Plc

•           Baxter International

•           Boehringer Ingelheim Gmb

•           Cohero Health

•           Glaxosmithcline PLC

•           Merck & Co.

•           Novartis AG, Opko Health

•           Philips Healthcare

•           Smith Medicals Inc.

•           Sunovion Pharmaceuticals Inc.

•           Teva Pharmaceuticals

•           3M Healthcare